XGN Stock Summary and Trading Ideas (Exagen | NASDAQ:XGN)

Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.

Exagen trades on the NASDAQ stock market under the symbol XGN.

As of June 22, 2026, XGN stock price declined to $4.34 with 94,716 million shares trading.

XGN has a beta of 1.92, meaning it tends to be more sensitive to market movements. XGN has a correlation of 0.10 to the broad based SPY ETF.

XGN has a market cap of $104.78 million. This is considered a Micro Cap stock.

Last quarter Exagen reported $17 million in Revenue and -$.17 earnings per share. This beat revenue expectation by $869,144 and exceeded earnings estimates by $.08.

In the last 3 years, XGN traded as high as $12.23 and as low as $1.30.

The top ETF exchange traded funds that XGN belongs to (by Net Assets): VTI, VXF, IWC, DFAS, DFMC.

XGN has underperformed the market in the last year with a price return of -41.0% while the SPY ETF gained +26.6%. However, in the short term, XGN had mixed performance relative to the market. It has outperformed in the last 3 months, returning +43.7% vs +13.2% return in SPY. But in the last 2 weeks, XGN shares have been beat by the market, returning -9.4% compared to an SPY return of -1.4%.

XGN support price is $4.27 and resistance is $4.82 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that XGN shares will trade within this expected range on the day.